Sarah Rhead

Publications by Year

Research Areas

SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Vaccine Coverage and Hesitancy, Bacterial Infections and Vaccines, Immunotherapy and Immune Responses

Most-Cited Works

• → Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK(2020)4,980 cited
• → Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant(2021)1,318 cited
• → Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial(2021)255 cited
• → Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial(2021)159 cited
• → Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa(2021)122 cited
• → Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial(2022)41 cited
• → Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV(2022)40 cited
• → Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial(2022)25 cited
• → ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV(2021)9 cited
• → Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection(2021)7 cited